Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

Oncogene

Volumn 28, Issue 2, 2009, Pages 231-242

  Hatano, K ^a   Kikuchi, J ^a   Takatoku, M ^a   Shimizu, R ^a   Wada, T ^a   Ueda, M ^a   Nobuyoshi, M ^a   Oh, I ^a   Sato, K ^a   Suzuki, T ^a   Ozaki, K ^a   Mori, M ^a   Nagai, T ^a   Muroi, K ^a   Kano, Y ^b   Furukawa, Y ^a   Ozawa, K ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

Author keywords

Bortezomib; Cell adhesion; Drug resistance; Myeloma; VLA 4

Indexed keywords

ALPHA4 INTEGRIN; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; BORTEZOMIB; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; DOXORUBICIN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN SUBUNIT; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SYNDECAN 1; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL;

ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DEXAMETHASONE; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRIN ALPHA CHAINS; INTEGRIN ALPHA4; INTEGRIN ALPHA4BETA1; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PYRAZINES; VINCRISTINE;

EID: 58249120680     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.385     Document Type: Article

References (41)

1. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-κB pathwaysby diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
2. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. (1996). Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involvesactivation of NF-κB. Blood 87: 1104-1112.
3. Cook G, Dumbar M, Franklin IM. (1997). The role of adhesion moleculesin multiple myeloma. Acta Haematol 97: 81-89.
4. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M et al. (2005). Zoledronic acid down-regulates adhesion moleculesof bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104: 118-125.
5. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. (1999). Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-1667.
6. Davies AM, Lara Jr PN, Mack PC, Gandara DR. (2007). Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13: 4647s-4651s.
7. Dolcet X, Llobet D, Pallares J. (2005). NF-κB in development and progression of human cancer. Virchows Arch 446: 475-482.
8. Drexler HG, Matsuo Y, MacLeod RA. (2003). Persistent use of false myeloma cell lines. Hum Cell 16: 101-105.
9. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. (2005). Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 19: 260-267.
10. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. (2006). Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874.
11. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19: 4319-4327.
12. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
13. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. (2001). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
14. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. (2006). Bortezomib interactions with chemotherapy agentsin acute leukemia in vitro. Cancer Chemother Pharmacol 58: 13-23.
15. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. (2007). Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12: 131-144.
16. Kikuchi J, Ozaki H, Nonomura C, Shinohara H, Iguchi S, Nojiri H et al. (2005). Transfection of antisense core 2 β1,6-N- acetylglucosaminyltransferase-1 cDNA suppresses selectin ligand expression and tissue infiltration of B-cell precursor leukemia cells. Leukemia 19: 1934-1940.
17. Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K et al. (2007). E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. Stem Cells 25: 2439-2447.
18. Kirschner KM, Wagner N, Wagner KD, Wellmann S, Scholz H. (2006). The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the α4 integrin gene. J Biol Chem 281: 31930-31939.
19. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33.
20. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. (2003). Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 22: 2417-2421.
21. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. (1995). Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258.
22. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. (2003). Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9: 1158-1165.
23. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR et al. (2000). Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood 96: 1953-1960.
24. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. (2002). Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525-4530.
25. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M et al. (2006). Severe pulmonary complicationsin Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107: 3492-3494.
26. Mori T, Kiyono T, Imabayashi H, Takeda Y, Tsuchiya K, Miyoshi S et al. (2005). Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol 25: 5183-5195.
27. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ et al. (2004). Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104: 2149-2154.
28. Nefedova Y, Landowski TH, Dalton WS. (2003). Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17: 1175-1182.
29. Noborio-Hatano K, Kano Y, Akustu M, Kikuchi J, Ueda M, Takatoku M et al. (2007). Effects of bortezomib in combination with conventional drugs against human lymphoid cell lines. Jpn J Clin Hematol 48: 1093a.
30. Odgerel T, Kikuchi J, Wada T, Shimizu R, Futaki K, Kano Y et al. (2008). The FLT3 inhibitor PKC412 exerts differential cell cycle effectson leukemic cells depending on the presence of FLT3 mutations. Oncogene 27: 3102-3110.
31. Olson DL, Burkly LC, Leone DR, Dolinski BM, Lobb RR. (2005). Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 4: 91-99.
32. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. (2001). Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98: 11581-11586.
33. Pfaffl MW. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid Res 29: e45.
34. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617.
35. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. (2005). Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498.
36. Rosen GD, Barks JL, Iademarco MF, Fisher RJ, Dean DC. (1994). An intricate arrangement of binding sites for the Ets family of transcription factors regulates activity of the α4 integrin gene promoter. J Biol Chem 269: 15652-15660.
37. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G. (2006). Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 21: 218-222.
38. Takatoku M, Noborio-Hatano K, Takahashi S, Kikuchi S, Mori M, Muroi K et al. (2004). Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma. Jpn J Clin Hematol 45: 144-148.
39. Tatsumi T, Shimazaki C, Goto H, Araki S, Sudo Y, Yamagata N et al. (1996). Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 87: 837-842.
40. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G et al. (2006). Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 12: 591-599.
41. Zutter MM, Ryan EE, Painter AD. (1997). Binding of phosphorylated Sp1 protein to tandem Sp1 binding sites regulates α2 integrin gene core promoter activity. Blood 90: 678-689.